Investigators at the National Institute of Neurological Disorders and Stroke (NINDS) seek persons with Parkinson’s disease for a research study. The study will determine if the experimental drug JP-1730, when compared to a placebo, will help control both the symptoms of Parkinson’s disease and the complications of long-term treatment.
Eligible participants are those who find standard medications to be less effective than before, are 30 to 80 years of age, and are experiencing abnormal involuntary movements (dyskinesias). Persons with heart or lung disease, and those who are pregnant or breast feeding, will not be eligible.
The study, which lasts approximately 5 weeks and involves a short inpatient stay each week, will take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH. This study is conducted under safety and testing standards of the Department of Health and Human Services.
To refer eligible patients, physicians should send a letter of referral and case summary to Dr. Thomas Chase, Chief, Experimental Therapeutics Branch, NINDS, NIH, Building 10, Room 5C106, 10 Center Drive MSC 1406, Bethesda, MD 20892-1406; fax: 301-496-6609. Please call Deserea Russell with any questions at 301-496-4604 or 1-800-362-3479. Refer to study number: 02-N-0236.